NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

Add Yahoo as a preferred source to see more of our stories on Google. A Nature Immunology study suggests PARP inhibitors can reprogram CD8 T cells into longer-lasting “superior memory” cancer fighters ...

Years before he conducted the research that would earn him a Nobel Prize in Physiology and Medicine, Shinya Yamanaka, MD, ...

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...

New York Blood Center Enterprises’ (NYBCe) Lindsley F. Kimball Research Institute (LFKRI) today announced a scientific ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into ...

Parvalbumin (PV) interneurons act as the brain’s rhythm keepers. By regulating local circuit activity and maintaining excitation–inhibition balance, they help stabilize cortical network function. When ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

Researchers in Japan have developed a form of stem cell therapy that "reverses" paralysis. Though the treatment has only seen a 50% success rate so far, two of the four people who received it have ...